ABT — Abbott Laboratories
Type: stock | Currency: USD | Sector: Health Care
Analysis update required
The stored signal has incomplete price provenance. It is shown only as historical information. ADD is the original model label, not a newly validated BUY.
Experimental technical research, not a fair-value assessment or personalized investment recommendation.
Stored assessment, historical plan and data provenance
Original action: ADD
Signal recorded at: 2026-11-18T07:56:37.344086+00:00
Data fetched at: N/A
Engine: N/A
Price basis: N/A
Technical score: N/A — not a probability
Why this assessment?
Fused signal based on technical setup and 10 recent news articles. News bias: 0.24, news strength: 0.85.
Time horizon: Days to weeks — fixed heuristic, not a forecast
Targets are stored technical levels, not estimates of intrinsic value. Previous stop/target events have not been integrated into this screen.
The temporary age rule flags prices more than three calendar days old. It is not exchange-calendar validation.
Calculation metadata
{}View scores, stored reasons and news
Latest stored ranking
Date: 2026-11-18
Stored rank: 82
Stored overall: 46.79
Model classification: watchlist
The overall score is experimental, not a fair-value estimate or investment recommendation.
Latest scores
Score date: 2026-11-18
Safety proxy: higher means better on the selected risk indicators; it does not measure total investment risk.
Heuristic value-trap flag: False
View full score breakdown and raw metrics
{
"risk": {
"leverage_score": 0.945505,
"liquidity_score": 0.5458333333333334,
"volatility_score": 1.0
},
"value": {
"pb_score": 0.48918609999999996,
"pe_score": 0.0,
"dividend_score": 1.0,
"ev_ebitda_score": 0.1251428571428571
},
"quality": {
"roe_score": 0.45689994999999994,
"growth_score": 0.9666666666666667,
"margin_score": 0.48735
},
"raw_metrics": {
"beta": 0.537,
"ev_ebitda": 18.248,
"forward_pe": 17.636942,
"net_margin": 0.09747,
"trailing_pe": 39.070892,
"current_ratio": 1.455,
"price_to_book": 3.5540695,
"debt_to_equity": 60.899,
"dividend_yield": 2.41,
"revenue_growth": 0.145,
"operating_margin": 0.15648,
"return_on_equity": 0.09137999
}
}
Latest active signal
Signal date: 2026-11-18T07:56:37.344086+00:00
Type: tactical
Action label: add
Model confidence: 54.00
Confidence is a heuristic model output, not a calibrated probability of profit.
Fused signal based on technical setup and 10 recent news articles. News bias: 0.24, news strength: 0.85.
Stored reasons
- news: Positive recent news supports the existing technical setup | High news impact detected | Technical confidence: 50.00 | News bias: 0.24 | News strength: 0.85 | Fused confidence: 54.00 | Recent articles analyzed: 10 | Previous technical action: hold
Latest stored news
-
Abbott (ABT) Stock May Be 28% Undervalued Despite AI Testing Expansion
Yahoo | 2026-11-17T20:08:42+00:00
Keyword sentiment: 0.33 | Keyword impact: 1.00 -
How Long Can HeartFlow Keep Burning Cash?
Yahoo | 2026-11-17T17:38:01+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell
Benzinga | 2026-11-17T08:56:10+00:00
Keyword sentiment: 0.33 | Keyword impact: 1.00 -
The Winners Inside SCHD - November 2026
SeekingAlpha | 2026-11-16T22:36:40+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Is A Medicare Delay The Biggest Risk For DexCom Stock?
Yahoo | 2026-11-16T17:47:22+00:00
Keyword sentiment: -0.67 | Keyword impact: 2.00 -
Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing
Yahoo | 2026-11-16T17:45:00+00:00
Keyword sentiment: -0.33 | Keyword impact: 1.00 -
Global Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC Testing
Yahoo | 2026-11-16T17:27:00+00:00
Keyword sentiment: 1.00 | Keyword impact: 3.00 -
Abbott Laboratories Extends Change in Control Agreements to December 31, 2028
Fintel | 2026-11-16T16:21:29+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026
Yahoo | 2026-11-16T13:50:00+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00 -
Should You Buy Neurocrine Biosciences Stock For Its Cash?
Yahoo | 2026-11-16T13:42:12+00:00
Keyword sentiment: 0.00 | Keyword impact: 0.00